T1	PROC 36 51	Estudio abierto
T2	PROC 57 77	evaluar la seguridad
T3	Date 78 91	a largo plazo
T4	CHEM 95 102	BCX9930
T5	PROC 106 117	monoterapia
#1	AnnotatorNotes T5	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T6	LIVB 121 128	sujetos
#2	AnnotatorNotes T6	C0681850; Study Subject; Group
T7	DISO 133 168	hemoglobinuria paroxística nocturna
#3	AnnotatorNotes T7	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T8	Time 160 168	nocturna
T9	CHEM 201 208	BCX9930
T10	DISO 267 302	Hemoglobinuria Paroxística Nocturna
#4	AnnotatorNotes T10	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T11	DISO 327 330	HPN
#5	AnnotatorNotes T11	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T12	PROC 389 425	consentimiento informado por escrito
T13	LIVB 431 438	Mujeres
#6	AnnotatorNotes T13	C0043210; Woman; Population Group | C0242665; wife; Family Group
T14	Neg_cue 439 441	no
T15	PHYS 442 453	embarazadas
#7	AnnotatorNotes T15	C0033011; Pregnant Women; Population Group
T16	Negated 442 453	embarazadas
T17	Neg_cue 454 456	ni
T18	PHYS 457 466	lactantes
#8	AnnotatorNotes T18	C0021270; Infant; Age Group
T19	Negated 457 466	lactantes
T20	LIVB 476 483	sujetos
#9	AnnotatorNotes T20	C0681850; Study Subject; Group
T21	DISO 488 491	HPN
#10	AnnotatorNotes T21	C0024790; Paroxysmal nocturnal hemoglobinuria; Disease or Syndrome
T22	PROC 516 527	tratamiento
#11	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	PROC 536 551	estudio clínico
#12	AnnotatorNotes T23	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T24	CHEM 552 559	BCX9930
T25	LIVB 578 590	investigador
#13	AnnotatorNotes T25	C0035173; Research Personnel; Professional or Occupational Group
T26	Speculated 592 608	se beneficiarían
T27	PROC 615 635	tratamiento continuo
T28	CHEM 640 647	BCX9930
T29	LIVB 657 687	participantes de sexo femenino
T30	LIVB 791 806	mujer no fértil
T31	Neg_cue 797 799	no
T32	Negated 800 806	fértil
T33	LIVB 819 839	mujer en edad fértil
T34	Age 828 839	edad fértil
T35	PROC 863 884	método anticonceptivo
#14	AnnotatorNotes T35	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T36	Duration 938 945	30 días
T37	CHEM 976 983	BCX9930
T38	PROC 1019 1030	abstinencia
T39	LIVB 1053 1075	mujeres en edad fértil
T40	Age 1064 1075	edad fértil
T41	LIVB 1181 1189	paciente
#15	AnnotatorNotes T41	C0030705; Patients; Patient or Disabled Group
T42	LIVB 1199 1230	participantes de sexo masculino
T43	LIVB 1330 1337	hombres
#16	AnnotatorNotes T43	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T44	LIVB 1346 1361	pareja femenina
T45	Age 1365 1376	edad fértil
T46	LIVB 1391 1408	pareja embarazada
T47	PROC 1416 1434	usar preservativos
T48	Duration 1479 1486	90 días
T49	CHEM 1510 1517	BCX9930
T50	LIVB 1534 1540	pareja
#17	AnnotatorNotes T50	C0682323; Partner in relationship; Family Group
T51	PROC 1560 1581	método anticonceptivo
#18	AnnotatorNotes T51	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T52	PROC 1660 1671	abstinencia
T53	LIVB 1788 1796	paciente
#19	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 1817 1829	investigador
#20	AnnotatorNotes T54	C0035173; Research Personnel; Professional or Occupational Group
T55	LIVB 1848 1854	sujeto
#21	AnnotatorNotes T55	C0681850; Study Subject; Group
T56	PROC 1890 1904	procedimientos
T57	DISO 1999 2029	afección médica o psiquiátrica
T58	DISO 2069 2104	dependencia al alcohol o las drogas
T59	LIVB 2125 2137	investigador
#22	AnnotatorNotes T59	C0035173; Research Personnel; Professional or Occupational Group
T60	Spec_cue 2149 2154	pueda
T61	Speculated 2155 2182	interferir con la capacidad
T62	LIVB 2187 2193	sujeto
#23	AnnotatorNotes T62	C0681850; Study Subject; Group
T63	Speculated 2226 2244	aumentar el riesgo
T64	LIVB 2272 2278	sujeto
#24	AnnotatorNotes T64	C0681850; Study Subject; Group
T65	DISO 2287 2309	acontecimiento adverso
#25	AnnotatorNotes T65	C0877248; Adverse event; Pathologic Function
T66	DISO 2311 2313	AA
#26	AnnotatorNotes T66	C0000727; Abdomen, Acute; Sign or Symptom | C0002874; Aplastic Anemia; Disease or Syndrome | C0003486; Aortic Aneurysm; Disease or Syndrome | C0004031; Aspergillosis, Allergic Bronchopulmonary; Disease or Syndrome | C0085693; Acute appendicitis NOS (disorder); Disease or Syndrome | C0221014; Reactive systemic amyloidosis; Disease or Syndrome
T67	DISO 2375 2384	toxicidad
#27	AnnotatorNotes T67	C0600688; Toxic effect; Injury or Poisoning
T68	LIVB 2415 2427	investigador
#28	AnnotatorNotes T68	C0035173; Research Personnel; Professional or Occupational Group
T69	LIVB 2457 2463	sujeto
#29	AnnotatorNotes T69	C0681850; Study Subject; Group
T70	PROC 2483 2521	procedimientos específicos del estudio
T71	Neg_cue 2541 2543	no
T72	Negated 2550 2555	mejor
T73	LIVB 2564 2570	sujeto
#30	AnnotatorNotes T73	C0681850; Study Subject; Group
T74	PROC 2586 2616	evaluación de riesgo-beneficio
T75	Neg_cue 2620 2622	no
T76	PROC 2640 2660	tratamiento continuo
T77	Negated 2640 2660	tratamiento continuo
T78	Duration 2652 2660	continuo
T79	LIVB 2665 2671	sujeto
#31	AnnotatorNotes T79	C0681850; Study Subject; Group
T80	Frequency 2681 2687	diario
T81	CHEM 2691 2699	fármacos
#32	AnnotatorNotes T81	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T82	Date 2700 2711	actualmente
T83	CHEM 2737 2749	medicamentos
#33	AnnotatorNotes T83	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T84	Contraindicated 2737 2749	medicamentos
T85	DISO 2790 2807	Hipersensibilidad
#34	AnnotatorNotes T85	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T86	Speculated 2819 2829	sospechada
T87	CHEM 2832 2839	BCX9930
T88	CHEM 2860 2871	excipientes
#35	AnnotatorNotes T88	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T89	DISO 2897 2905	erupción
#36	AnnotatorNotes T89	C0015230; Exanthema; Sign or Symptom | C0302295; Eruptions; Pathologic Function
T90	CHEM 2917 2924	fármaco
#37	AnnotatorNotes T90	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T91	Neg_cue 2925 2927	no
T92	Negated 2931 2941	excluyente
T93	PROC 215 222	estudio
T94	Time 294 302	Nocturna
T95	PROC 762 769	estudio
T96	PROC 1451 1458	estudio
T97	PROC 1617 1624	estudio
T98	PROC 1951 1958	estudio
T99	PROC 2216 2222	ensayo
T100	PROC 920 927	estudio
T101	PROC 1305 1312	estudio
T102	Speculated 2790 2807	Hipersensibilidad
T103	Observation 364 369	capaz
T104	Observation 502 527	completado el tratamiento
T105	Observation 592 608	se beneficiarían
T106	Quantifier_or_Qualifier 800 806	fértil
T107	Quantifier_or_Qualifier 885 903	altamente efectivo
T108	CONC 960 972	última dosis
T109	CONC 1501 1506	dosis
T110	Quantifier_or_Qualifier 1582 1598	altamente eficaz
T111	Observation 1855 1931	cumpla adecuadamente con todos los procedimientos y restricciones de estudio
T112	Quantifier_or_Qualifier 2030 2056	clínicamente significativa
T113	Food 2084 2091	alcohol
T114	CONC 2155 2165	interferir
T115	Observation 2199 2222	participar en el ensayo
T116	Observation 2248 2261	participación
T117	Quantifier_or_Qualifier 2315 2323	continuo
T118	Observation 2341 2367	anormalidad de laboratorio
T119	Observation 2429 2452	compromete la capacidad
T120	Quantifier_or_Qualifier 2931 2941	excluyente
T121	Patient 121 128	sujetos
T122	History_of 201 208	BCX9930
T123	Patient 431 438	Mujeres
T124	Patient 457 466	lactantes
T125	Patient 476 483	sujetos
T126	History_of 516 527	tratamiento
T127	History_of 536 551	estudio clínico
T128	Other 578 590	investigador
T129	Patient 657 687	participantes de sexo femenino
T130	Patient 791 799	mujer no
T131	Patient 819 839	mujer en edad fértil
T132	Patient 1053 1075	mujeres en edad fértil
T133	Patient 1181 1189	paciente
T134	Patient 1199 1230	participantes de sexo masculino
T135	Patient 1330 1337	hombres
T136	Family_member 1346 1361	pareja femenina
T137	Family_member 1391 1397	pareja
T138	Family_member 1534 1540	pareja
T139	Patient 1788 1796	paciente
T140	Other 1817 1829	investigador
T141	Patient 1848 1854	sujeto
T142	Other 2125 2137	investigador
T143	Patient 2187 2193	sujeto
T144	Patient 2272 2278	sujeto
T145	Other 2415 2427	investigador
T146	Patient 2457 2463	sujeto
T147	Patient 2564 2570	sujeto
T148	Patient 2665 2671	sujeto
T149	History_of 2790 2807	Hipersensibilidad
T150	History_of 2897 2905	erupción
